n-methylscopolamine has been researched along with desethyloxybutynin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawashima, A; Oki, T; Uchida, M; Yamada, S | 1 |
| Oki, T; Toma-Okura, A; Yamada, S | 1 |
| Fujino Oki, T; Kato, Y; Kurosawa, S; Nanri, M; Uchida, S; Yamada, S; Yoshida, K | 1 |
3 other study(ies) available for n-methylscopolamine and desethyloxybutynin
| Article | Year |
|---|---|
In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
Topics: Analysis of Variance; Animals; Cholinergic Antagonists; Colon; Dose-Response Relationship, Drug; Injections, Intravenous; Male; Mandelic Acids; Muscarinic Antagonists; Myocardium; N-Methylscopolamine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Saliva; Submandibular Gland; Time Factors; Urinary Bladder | 2005 |
Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Male; Mandelic Acids; N-Methylscopolamine; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Saliva; Urinary Bladder Diseases | 2006 |
Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
Topics: Analysis of Variance; Animals; Benzilates; Brain; Calcium Channels, L-Type; Diltiazem; Isradipine; Male; Mandelic Acids; N-Methylscopolamine; Protein Binding; Rats; Rats, Sprague-Dawley; Tritium; Urinary Bladder; Verapamil | 2007 |